Antisense Oligonucleotide VO659 Reduces Mutant Huntingtin Protein, Interim Phase 1/2 Data Show

Published Date: 15 Sep 2024

VO659 was considered safe and well tolerated, with treated patients showing no sustained increase in neurofilament light protein through day 85 of treatment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot